Gintant相关文献与解析，生知库 | 链接生命科学的每一步

Valentin, Jean-Pierre; Hoffmann, Peter; Ortemann-Renon, Catherine; Koerner, John; Pierson, Jennifer; Gintant, Gary; Willard, James; Garnett, Christine; Skinner, Matthew; Vargas, Hugo M; Wisialowski, Todd; Pugsley, Michael K

Human

发表日期：2022

文献求助收藏

Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective

是时候进行全面整合的非临床-临床风险评估，以简化QT间期延长责任认定流程了：制药行业的视角

期刊:Clinical Pharmacology & Therapeutics

影响因子:5.5

doi:10.1002/cpt.2029

Vargas, Hugo M; Rolf, Michael G; Wisialowski, Todd A; Achanzar, William; Bahinski, Anthony; Bass, Alan; Benson, Charles T; Chaudhary, Khuram W; Couvreur, Nicolas; Dota, Corina; Engwall, Michael J; Michael Foley, C; Gallacher, David; Greiter-Wilke, Andrea; Guillon, Jean-Michel; Guth, Brian; Himmel, Herbert M; Hegele-Hartung, Christa; Ito, Maki; Jenkinson, Stephen; Chiba, Katsuyoshi; Lagrutta, Armando; Levesque, Paul; Martel, Eric; Okai, Yoshiko; Peri, Ravikumar; Pointon, Amy; Qu, Yusheng; Teisman, Ard; Traebert, Martin; Yoshinaga, Takashi; Gintant, Gary A; Leishman, Derek J; Valentin, Jean-Pierre

发表日期：2021

文献求助收藏

Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells.

药物对重组细胞中人类心脏电流影响的自动膜片钳评估的跨站点和跨平台变异性

期刊:Scientific Reports

影响因子:3.9

doi:10.1038/s41598-020-62344-w

Kramer James, Himmel Herbert M, Lindqvist Anders, Stoelzle-Feix Sonja, Chaudhary Khuram W, Li Dingzhou, Bohme Georg Andrees, Bridgland-Taylor Matthew, Hebeisen Simon, Fan Jingsong, Renganathan Muthukrishnan, Imredy John, Humphries Edward S A, Brinkwirth Nina, Strassmaier Tim, Ohtsuki Atsushi, Danker Timm, Vanoye Carlos, Polonchuk Liudmila, Fermini Bernard, Pierson Jennifer Beck, Gintant Gary

Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association

利用人诱导多能干细胞衍生的心肌细胞进行临床前抗癌药物心脏毒性测试：美国心脏协会科学声明

期刊:Circulation Research

影响因子:16.2

doi:10.1161/RES.0000000000000291

Gintant, Gary; Burridge, Paul; Gepstein, Lior; Harding, Sian; Herron, Todd; Hong, Charles; Jalife, José; Wu, Joseph C

Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes

体外细胞测试平台在药物早期研发中检测药物诱导正性肌力效应的考量。第二部分：利用人诱导多能干细胞来源的心肌细胞设计和构建具有生理相关性的微系统以检测心脏收缩力

期刊:Frontiers in Pharmacology

影响因子:4.8

doi:10.3389/fphar.2019.00934

Ribeiro, Alexandre J S; Guth, Brian D; Engwall, Michael; Eldridge, Sandy; Foley, C Michael; Guo, Liang; Gintant, Gary; Koerner, John; Parish, Stanley T; Pierson, Jennifer B; Brock, Mathew; Chaudhary, Khuram W; Kanda, Yasunari; Berridge, Brian

Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms

早期药物研发中用于检测药物诱导的不良正性肌力效应的体外细胞测试平台的考量因素。第一部分：新型测试平台开发的一般性考量因素

期刊:Frontiers in Pharmacology

影响因子:4.8

doi:10.3389/fphar.2019.00884

Guth, Brian D; Engwall, Michael; Eldridge, Sandy; Foley, C Michael; Guo, Liang; Gintant, Gary; Koerner, John; Parish, Stanley T; Pierson, Jennifer B; Ribeiro, Alexandre J S; Zabka, Tanja; Chaudhary, Khuram W; Kanda, Yasunari; Berridge, Brian

细胞生物学

发表日期：2019

文献求助收藏

Assessing cardiac safety in oncology drug development

评估肿瘤药物研发中的心脏安全性

期刊:American Heart Journal

影响因子:3.5

doi:10.1016/j.ahj.2019.04.010

Seltzer, Jonathan H; Gintant, Gary; Amiri-Kordestani, Laleh; Singer, Jack; Koplowitz, Luana Pesco; Moslehi, Javid J; Barac, Ana; Yu, Anthony F

T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization

T向量速度：一种用于识别药物对心室复极化影响的新型心电图生物标志物

期刊:PLoS One

影响因子:2.6

doi:10.1371/journal.pone.0204712

Bystricky, Werner; Maier, Christoph; Gintant, Gary; Bergau, Dennis; Kamradt, Kent; Welsh, Patrick; Carter, David

发表日期：2019

文献求助收藏

International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment

一项评估人诱导多能干细胞衍生心肌细胞药物致心律失常潜能的国际多中心研究

期刊:Cell Reports

影响因子:6.9

doi:10.1016/j.celrep.2018.08.079

Blinova, Ksenia; Dang, Qianyu; Millard, Daniel; Smith, Godfrey; Pierson, Jennifer; Guo, Liang; Brock, Mathew; Lu, Hua Rong; Kraushaar, Udo; Zeng, Haoyu; Shi, Hong; Zhang, Xiaoyu; Sawada, Kohei; Osada, Tomoharu; Kanda, Yasunari; Sekino, Yuko; Pang, Li; Feaster, Tromondae K; Kettenhofen, Ralf; Stockbridge, Norman; Strauss, David G; Gintant, Gary

The Use of Ratiometric Fluorescence Measurements of the Voltage Sensitive Dye Di-4-ANEPPS to Examine Action Potential Characteristics and Drug Effects on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

利用电压敏感染料Di-4-ANEPPS的比率荧光测量法检测人诱导多能干细胞衍生心肌细胞的动作电位特征和药物作用

期刊:Toxicological Sciences

影响因子:4.1

doi:10.1093/toxsci/kfw171

Hortigon-Vinagre, M P; Zamora, V; Burton, F L; Green, J; Gintant, G A; Smith, G L

The Challenges of Predicting Drug-Induced QTc Prolongation in Humans

预测药物诱发的人类QTc间期延长的挑战

Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective

是时候进行全面整合的非临床-临床风险评估，以简化QT间期延长责任认定流程了：制药行业的视角

Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells.

药物对重组细胞中人类心脏电流影响的自动膜片钳评估的跨站点和跨平台变异性

Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association

利用人诱导多能干细胞衍生的心肌细胞进行临床前抗癌药物心脏毒性测试：美国心脏协会科学声明

Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Drug-Induced Inotropic Effects in Early Drug Development. Part 2: Designing and Fabricating Microsystems for Assaying Cardiac Contractility With Physiological Relevance Using Human iPSC-Cardiomyocytes

体外细胞测试平台在药物早期研发中检测药物诱导正性肌力效应的考量。第二部分：利用人诱导多能干细胞来源的心肌细胞设计和构建具有生理相关性的微系统以检测心脏收缩力

Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms

早期药物研发中用于检测药物诱导的不良正性肌力效应的体外细胞测试平台的考量因素。第一部分：新型测试平台开发的一般性考量因素

Assessing cardiac safety in oncology drug development

评估肿瘤药物研发中的心脏安全性

T vector velocity: A new ECG biomarker for identifying drug effects on cardiac ventricular repolarization

T向量速度：一种用于识别药物对心室复极化影响的新型心电图生物标志物

International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment

一项评估人诱导多能干细胞衍生心肌细胞药物致心律失常潜能的国际多中心研究

The Use of Ratiometric Fluorescence Measurements of the Voltage Sensitive Dye Di-4-ANEPPS to Examine Action Potential Characteristics and Drug Effects on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

利用电压敏感染料Di-4-ANEPPS的比率荧光测量法检测人诱导多能干细胞衍生心肌细胞的动作电位特征和药物作用